经鼻持续气道正压通气联合肺表面活性物质治疗呼吸窘迫综合征早产儿14例

目的研究呼吸窘迫综合征早产儿经鼻持续气道正压通气(NCPAP)联合肺表面活性物质的治疗。方法选取本科室诊治呼吸窘迫综合征早产儿28例为研究对象,分为MV组14例,采用常规的机械通气疗法并辅助肺表面活性物质治疗,NCPAP组14例采用经鼻持续气道正压通气疗法并辅助肺表面活性物质治疗,分析相关疗法对患儿的临床疗效。结果2组患儿随着治疗时间延长,与治疗前指标对比,治疗后6、12、24 h的p H值、p(O2)及p(O_2)/FiO_2水平上升,p(CO_2)水平下降,患儿病情显著改善(P0.05);治疗后,2组患儿的心率、呼吸频率、平均氧合指数等体征有明显改善,病情几乎恢复到正常,2组以上指标差异显著(P0.05);NCPAP的有效率为85.71%,远高于MV的64.29%,2组对比差异有统计学意义(P0.05);NCPAP患儿不良反应病发率为14.28%,而MV患儿不良反应病发率为35.71%,2组不良反应病发率对比差异显著(P0.05)。结论采用NCPAP联合肺表面活性物质疗法可以有效改善早产儿呼吸窘迫综合征患儿的病情,提高患儿生存质量,且疗效突出,并发症较少。

Effect of nasal continuons positive airway pressure combined with pulmonary surfactant on treating 14 premature infants with respiratory distress syndrome

Objective To study the effect of nasal continuons positive airway pressure (NCPAP) combined with pulmonary surfactant for premature infants with respiratory distress syndrome.Methods A total of 28 premature infants with respiratory distress syndrome were divided into MV group with 14 patients given mechanical ventilation therapy and conventional assisted pulmonary surfactant therapy,and NCPAP group with 14 patients given nasal continuous positive airway pressure therapy and pulmonary surface active treatment,clinical efficacy were analyzed.Results With the treatment time prolonging,compared with treatment indices before,pH value p(O2) and p(O2)/FiO2 levels after treatment increased at 6,12,24 h,and p(CO2) decreased,the symptoms of patients was improved significantly (P<0.05);After treatment,heart rate,respiratory frequency,average oxygen index and other signs were improved significantly,the disease almost returned to normal.There was significant difference in above indicators in two groups(P<0.05);The NCPAP rate was 85.71%,which was higher than 64.29% of MV group (P<0.05);Incidence of adverse reaction was 14.28% in NCPAP group,and 35.71% in MV group,and there was significant difference in the incidence of adverse reactions between the two groups (P<0.05).Conclusion NCPAP combined with pulmonary surfactant therapy can effectively improve life quality of children with respiratory distress syndrome in premature children,improve efficacy,and reduce complications.